The National Healthcare Security Administration Gave a Positive Reply to the Proposal of Incorporating the Assisted Treatment of “Infertility” into Medical Insurance
In March this year, during the fourth session of the 13th national people's congress, Gao Li, a deputy to the national people's congress and secretary and director of AnHui Disabled Person’s Federation, submitted a proposal on the incorporation of the diagnosis and treatment of "infertility and assisted reproductive technology" in the national medical insurance to improve population growth.
On September 15, the “Reply of the National Healthcare Security Administration to Recommendation No.5581 of the Fourth Session of the 13th National People’s Congress” (hereinafter referred to as the “Reply”) on the website of the National Healthcare Security Administration announced the specific contents of the reply to the incorporation of assisted treatment of “infertility” in the national medical insurance to improve population growth ".
The National Healthcare Security Administration pointed out, “In order to promote the long-term balanced development of the population, in terms of diagnosis and treatment programs, we will guide all regions to gradually incorporate the technically mature, safe and reliable therapeutic assisted reproductive technology with controllable cost that can be borne by the medical insurance into the medical insurance based on guarantying basically, scientific calculation and full demonstration.”
The National Healthcare Security Administration said that it will further perfect the policy with relevant departments to improve the protection level for infertility patients.
According to the survey, the incidence of infertility in China has climbed to 12.5%–15% and is still increasing. The infertile cannot be ignored. In the past, infertility and assisted reproductive technology were not covered by the medical insurance because they did not belong to the disease treatment, causing a great burden to patients and families. The costs related to infertility and diagnosis and treatment by assisted reproductive technology according to the proportion should be incorporated into medical insurance and the pregnancy insurance system should be established to effectively protect the fertility rights and increase the chance of birth.
In recent years, the national policies related to the population are increasing, which demonstrates that improving fertility and ensuring prenatal and postnatal care is the top priority of the current national population strategy. The assisted reproductive industry, hospitals, equipment and pharmaceutical companies will embrace great opportunities. Basecare, as a leader in gene testing of assisted reproduction, will undoubtedly benefit a lot.
Basecare, listed in Hong Kong at the beginning of this year, is the leader in reproduction, the NGS segment market and dedicated to the R&D and clinical application of high-throughput sequencing technology in reproductive health. Basecare has a sound layout in assisted reproduction, and has developed corresponding kits from the pre-implantation stage to the pre-natal and post-natal stages. It is the only company in China with a product portfolio covering all key stages of the whole reproductive cycle.
2021 is the first year of the “14th Five-Year Plan”. We hope that in the new round of innovation cycle, the assisted reproduction field will develop better under the sustained and strong support of the national policy.